- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077271
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
August 20, 2012 updated by: Abbott
PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA Over 3 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria
Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against respiratory syncytial virus (RSV) infection as shown in the IMpact study.
Many factors such as parents' knowledge of burden of respiratory syncytial virus disease or physicians' satisfaction with Synagis as well as the appropriate use of the product might influence compliance.
The primary objective of this observational study is to evaluate the compliance to Synagis under daily pediatricians practice conditions in premature infants 33 to 35 weeks gestational age (wGA).
Palivizumab, monoclonal antibody for passive immunoprophylaxis against severe respiratory syncytial virus disease, was administered according to usual clinical practice.
Compliance was assessed using four criteria: The number of injections per participant per respiratory syncytial virus season, the body site where injections were administered, the interval in days between injections, and the dosage per administration.
Originally the study was to include two respiratory syncytial virus seasons but was extended to a third season.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
124
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amstetten, Austria, 3300
- Site Reference ID/Investigator# 27772
-
Amstetten, Austria, 3300
- Site Reference ID/Investigator# 52871
-
Feldkirch, Austria, 6800
- Site Reference ID/Investigator# 52873
-
Ganserndorf, Austria, 2230
- Site Reference ID/Investigator# 40437
-
Hollabrunn, Austria, 2020
- Site Reference ID/Investigator# 30843
-
Judenburg, Austria, 8750
- Site Reference ID/Investigator# 27767
-
Klagenfurt, Austria, 9020
- Site Reference ID/Investigator# 27770
-
Klosterneuburg, Austria, 3400
- Site Reference ID/Investigator# 27777
-
Krems, Austria, 3500
- Site Reference ID/Investigator# 30842
-
Leonding, Austria, 4060
- Site Reference ID/Investigator# 27771
-
Linz, Austria, 4020
- Site Reference ID/Investigator# 52867
-
Linz, Austria, 4020
- Site Reference ID/Investigator# 58943
-
Linz, Austria, 4030
- Site Reference ID/Investigator# 18603
-
Linz, Austria, 4040
- Site Reference ID/Investigator# 40445
-
Linz, Austria, 4040
- Site Reference ID/Investigator# 52874
-
Mattersburg, Austria, 7210
- Site Reference ID/Investigator# 52870
-
Neufeld, Austria, 2491
- Site Reference ID/Investigator# 48262
-
Purkersdorf, Austria, 3002
- Site Reference ID/Investigator# 27775
-
Scheibbs, Austria, 3270
- Site Reference ID/Investigator# 27765
-
Schorfling, Austria, 4861
- Site Reference ID/Investigator# 40440
-
St Polten, Austria, 3100
- Site Reference ID/Investigator# 30850
-
Telfs, Austria, 6410
- Site Reference ID/Investigator# 27764
-
Traisen, Austria, 3160
- Site Reference ID/Investigator# 40439
-
Tulln, Austria, 3400
- Site Reference ID/Investigator# 30848
-
Tulln, Austria, 3430
- Site Reference ID/Investigator# 27776
-
Vienna, Austria, 1020
- Site Reference ID/Investigator# 30845
-
Vienna, Austria, 1030
- Site Reference ID/Investigator# 30849
-
Vienna, Austria, 1030
- Site Reference ID/Investigator# 40432
-
Vienna, Austria, 1030
- Site Reference ID/Investigator# 40447
-
Vienna, Austria, 1040
- Site Reference ID/Investigator# 27773
-
Vienna, Austria, 1060
- Site Reference ID/Investigator# 52879
-
Vienna, Austria, 1090
- Site Reference ID/Investigator# 27769
-
Vienna, Austria, 1100
- Site Reference ID/Investigator# 40446
-
Vienna, Austria, 1100
- Site Reference ID/Investigator# 52878
-
Vienna, Austria, 1110
- Site Reference ID/Investigator# 27774
-
Vienna, Austria, 1120
- Site Reference ID/Investigator# 27762
-
Vienna, Austria, 1150
- Site Reference ID/Investigator# 27763
-
Vienna, Austria, 1190
- Site Reference ID/Investigator# 40442
-
Vienna, Austria, 1200
- Site Reference ID/Investigator# 30851
-
Vienna, Austria, 1200
- Site Reference ID/Investigator# 58942
-
Vienna, Austria, 1210
- Site Reference ID/Investigator# 30846
-
Vienna, Austria, 1210
- Site Reference ID/Investigator# 30847
-
Vienna, Austria, 1210
- Site Reference ID/Investigator# 57793
-
Vienna, Austria, 1220
- Site Reference ID/Investigator# 30852
-
Vienna, Austria, 1220
- Site Reference ID/Investigator# 40425
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Medical practices specialized in pediatrics.
Description
Inclusion Criteria:
- Premature infant 33 to 35 weeks gestational age
- Younger than 3 months at respiratory syncytial virus season start
- At least 4 points according to the Austrian risk score according to Austrian guidelines: 1 point younger than 3 months (at start of respiratory syncytial virus season), 1 point neurologic disease, 1 point weight less than 10th percentile, 1 point discharge from hospital during respiratory syncytial virus season (1 Oct - 30 March), 1 point older siblings, 0.5 points multiple births, 0.5 points day care attendance, 0.5 points passive tobacco smoke exposure, 0.5 points socio-economic status (overcrowding)
- Synagis application (prescription)
- Signed authorization form for data use (parental authorization)
Exclusion Criteria:
- Patients without Synagis prescription
Patients who meet contraindications as outlined in the latest version of Synagis summary of product characteristics (SmPC):
- Patients with known hypersensitivity to palivizumab or any component of the formulation or other humanized monoclonal antibodies
- Patients with chronic lung disease
- Patients with congenital heart disease
- Greater than 36 weeks gestational age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Premature infants 33 - 35 wGA prophylaxed with palivizumab
Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Injections Per Patient Per Season
Time Frame: One RSV season (5 months)
|
The average number of injections administered per participant within a respiratory syncytial virus season.
|
One RSV season (5 months)
|
Body Site of Injections Per Administration
Time Frame: One RSV season (5 months)
|
The body site of injection administration for participants at each study visit.
|
One RSV season (5 months)
|
Interval Between Administrations
Time Frame: One RSV season (5 months)
|
The average number of days that elapsed between palivizumab injections administered at the previous study visit.
|
One RSV season (5 months)
|
Dosage Per Administration
Time Frame: One RSV season (5 months)
|
The median dose and range of palivizumab (milligrams) that was administered at each study visit.
|
One RSV season (5 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Pain During Injection According to Pain Scores (VAS and Modified Behavioral Pain Scale)
Time Frame: One RSV season (5 months)
|
The clinician who administered the palivizumab injection was asked to rate pain during injection using a visual analog scale (VAS) and the Modified Behavior Pain Scale (MBPS) as published by Carbajal et al., 2008.
The VAS ranged from 0 (no pain) to 100 (maximum pain).
The Modified Behavioral Pain Scale ranged from 0 (no pain) to 10 (maximum pain) through the evaluation of 3 items: Facial expressions, cry, and movements.
If more than one injection was given at a visit, then the first injection was rated.
|
One RSV season (5 months)
|
Parents Knowledge of Burden of RSV Disease Via Interview by Physician
Time Frame: One RSV season (5 months)
|
An informational brochure was given to parents of participants.
Parents were interviewed by the treating physician at the first study visit (V1) and last study visit (LSV) (or early termination visit [ET]) for those participants discontinuing from the study).
Parental knowledge of the burden of respiratory syncytial virus (RSV) disease was assessed using a questionnaire.
Parents were considered to have "good RSV awareness" if all questions were answered and at least 3 of the 4 questions regarding the burden of RSV disease were answered correctly.
|
One RSV season (5 months)
|
Effectiveness of Palivizumab at the End of the Observation Period is Checked by the Physician by Ranking in a Visible Analog Scale
Time Frame: One RSV season (5 months), end of study
|
The therapeutic effect of palivizumab was assessed by the treating physician using a visual analog scale from 0 to 10, where 0 indicated that palivizumab did not match expectations at all and 10 indicated that palivizumab met all expectations.
The physician rated palivizumab treatment for each participant at the last study visit (LSV) or, in the case of participants withdrawing from the study, at the early termination (ET) visit.
|
One RSV season (5 months), end of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Astrid Dworan-Timler, MD, Abbott Austria
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
February 25, 2010
First Submitted That Met QC Criteria
February 25, 2010
First Posted (Estimate)
March 1, 2010
Study Record Updates
Last Update Posted (Estimate)
August 21, 2012
Last Update Submitted That Met QC Criteria
August 20, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P11-040
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Infants
-
University of ManitobaCompleted
-
Selcuk UniversityCompletedPremature InfantsTurkey
-
Firat UniversityCompleted
-
Materna LaboratoriesCompleted
-
Radboud University Medical CenterUniversity Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Amsterdam... and other collaboratorsCompletedPremature Birth | Extremely Premature Infants
-
Hadassah Medical OrganizationWithdrawnPreterm Infants With White Matter Damage | Preterm Infants Developing Normally
-
Baylor College of MedicineMead Johnson Nutrition; The Children's Nutrition Research CenterActive, not recruiting
-
Baylor College of MedicineSuspendedPremature InfantsUnited States
-
Shanghai Children's HospitalChildren's Hospital affiliated to Chongqing Medical University; Xuzhou maternal...Not yet recruitingPremature Infants | NICU Infants | Conventional NBS-positive Infants